Clonal Analysis of Multipotent Stromal Cells Derived from CD271+ Bone Marrow Mononuclear Cells: Functional Heterogeneity and Different Mechanisms of Allosuppression

Overview

Journal Haematologica

Specialty Hematology

Date 2013 Aug 27

PMID 23975178

Citations 27

Authors

Zyrafete Kuci

Julia Seiberth

Hatixhe Latifi-Pupovci

Sibylle Wehner

Stefan Stein

Manuel Grez

Halvard Bonig

Ulrike Kohl

Thomas Klingebiel

Peter Bader

Selim Kuci

Affiliations

Soon will be listed here.

Abstract

Previous reports demonstrated a relationship between proliferation potential and trilineage differentiation in mesenchymal stromal cell-derived clones generated using plastic adherence (PA-MSCs). However, there are no reports presenting a clonal analysis of the proliferative potential, differentiation potential and allosuppressive effects of human mesenchymal stromal cell subsets. In this study, we performed a clonal analysis of mesenchymal stromal cells generated from human CD271(+) bone marrow mononuclear cells (CD271-MSCs). After transfection with the gene encoding green fluorescent protein, the cells were single-cell sorted and cultured for 2-4 weeks. A population doubling analysis demonstrated that 25% of CD271-MSC clones are fast-proliferating clones compared to only 10% of PA-MSC clones. Evaluation of the allosuppressive potential demonstrated that 81.8% of CD271-MSC clones were highly allosuppressive compared to only 58% of PA-MSC clones. However, no consistent correlation was observed between allosuppression and proliferative potential. Prostaglandin E2 levels were positively correlated with the allosuppressive activity of individual clones, suggesting that this molecule may be a useful predictive biomarker for the allosuppressive potential of mesenchymal stromal cells. In contrast, inhibitory studies of indoleamine 2,3 dioxygenase indicated that none of the clones used this enzyme to mediate their allosuppressive effect. Differentiation studies revealed the presence of tripotent, bipotent and unipotent CD271-MSC and PA-MSC clones which suppressed the allogeneic reaction to differing extents in vitro. In conclusion, our findings demonstrate differences between CD271-MSCs and PA-MSCs and indicate that neither proliferation potential nor differentiation potential represents a consistent predictive parameter for the immunomodulatory effects of either type of mesenchymal stromal cells.

Citing Articles

Paracrine- and cell-contact-mediated immunomodulatory effects of human periodontal ligament-derived mesenchymal stromal cells on CD4 T lymphocytes.

Behm C, Milek O, Rausch-Fan X, Moritz A, Andrukhov O Stem Cell Res Ther. 2024; 15(1):154.

PMID: 38816862 PMC: 11141051. DOI: 10.1186/s13287-024-03759-4.

Small volume bone marrow aspirates with high progenitor cell concentrations maximize cell therapy dose manufacture and substantially reduce donor hemoglobin loss.

Epah J, Spohn G, Preiss K, Muller M, Dorr J, Bauer R BMC Med. 2023; 21(1):360.

PMID: 37726769 PMC: 10510270. DOI: 10.1186/s12916-023-03059-3.

A New Perspective for Bone Tissue Engineering: Human Mesenchymal Stromal Cells Well-Survive Cryopreservation on β-TCP Scaffold and Show Increased Ability for Osteogenic Differentiation.

Leppik L, Gempp A, Kuci Z, Kuci S, Bader P, Bonig H Int J Mol Sci. 2022; 23(3).

PMID: 35163348 PMC: 8835857. DOI: 10.3390/ijms23031425.

Assessment of the Effect of Infliximab on Immunomodulation Properties of Mesenchymal Stem Cells .

Sakha Y, Ehsani E, Roshandel E, Jalili A, Vahdani N, Hajifathali A Adv Pharm Bull. 2021; 11(4):739-745.

PMID: 34888221 PMC: 8642797. DOI: 10.34172/apb.2021.083.

Steps Toward Standardized In Vitro Assessment of Immunomodulatory Equine Mesenchymal Stromal Cells Before Clinical Application.

Lee O, Koch T Stem Cells Dev. 2021; 31(1-2):18-25.

PMID: 34779250 PMC: 8792491. DOI: 10.1089/scd.2021.0189.

References

Oswald J, Boxberger S, Jorgensen B, Feldmann S, Ehninger G, Bornhauser M . Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells. 2004; 22(3):377-84. DOI: 10.1634/stemcells.22-3-377. View

Quirici N, Soligo D, Bossolasco P, Servida F, Lumini C, Deliliers G . Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies. Exp Hematol. 2002; 30(7):783-91. DOI: 10.1016/s0301-472x(02)00812-3. View

Phinney D . Functional heterogeneity of mesenchymal stem cells: implications for cell therapy. J Cell Biochem. 2012; 113(9):2806-12. DOI: 10.1002/jcb.24166. View

Rasmusson I, Ringden O, Sundberg B, Le Blanc K . Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res. 2005; 305(1):33-41. DOI: 10.1016/j.yexcr.2004.12.013. View

Hanagata N, Li X . Osteoblast-enriched membrane protein IFITM5 regulates the association of CD9 with an FKBP11-CD81-FPRP complex and stimulates expression of interferon-induced genes. Biochem Biophys Res Commun. 2011; 409(3):378-84. DOI: 10.1016/j.bbrc.2011.04.136. View

Potian J, Aviv H, Ponzio N, Harrison J, Rameshwar P . Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol. 2003; 171(7):3426-34. DOI: 10.4049/jimmunol.171.7.3426. View

Rasmusson I . Immune modulation by mesenchymal stem cells. Exp Cell Res. 2006; 312(12):2169-79. DOI: 10.1016/j.yexcr.2006.03.019. View

Mareddy S, Crawford R, Brooke G, Xiao Y . Clonal isolation and characterization of bone marrow stromal cells from patients with osteoarthritis. Tissue Eng. 2007; 13(4):819-29. DOI: 10.1089/ten.2006.0180. View

Nauta A, Fibbe W . Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007; 110(10):3499-506. DOI: 10.1182/blood-2007-02-069716. View

10.

Le Blanc K, Rasmusson I, Gotherstrom C, Seidel C, Sundberg B, Sundin M . Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol. 2004; 60(3):307-15. DOI: 10.1111/j.0300-9475.2004.01483.x. View

11.

Yanez R, Oviedo A, Aldea M, Bueren J, Lamana M . Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissue-derived mesenchymal stromal cells. Exp Cell Res. 2010; 316(19):3109-23. DOI: 10.1016/j.yexcr.2010.08.008. View

12.

Poloni A, Maurizi G, Rosini V, Mondini E, Mancini S, Discepoli G . Selection of CD271(+) cells and human AB serum allows a large expansion of mesenchymal stromal cells from human bone marrow. Cytotherapy. 2009; 11(2):153-62. DOI: 10.1080/14653240802582125. View

13.

Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni P, Matteucci P . Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002; 99(10):3838-43. DOI: 10.1182/blood.v99.10.3838. View

14.

Maccario R, Podesta M, Moretta A, Cometa A, Comoli P, Montagna D . Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica. 2005; 90(4):516-25. View

15.

Kuci Z, Kuci S, Zircher S, Koller S, Schubert R, Bonig H . Mesenchymal stromal cells derived from CD271(+) bone marrow mononuclear cells exert potent allosuppressive properties. Cytotherapy. 2011; 13(10):1193-204. DOI: 10.3109/14653249.2011.605118. View

16.

Kuci S, Kuci Z, Kreyenberg H, Deak E, Putsch K, Huenecke S . CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. Haematologica. 2010; 95(4):651-9. PMC: 2857196. DOI: 10.3324/haematol.2009.015065. View

17.

Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T . Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood. 2006; 109(1):228-34. DOI: 10.1182/blood-2006-02-002246. View

18.

Uccelli A, Moretta L, Pistoia V . Immunoregulatory function of mesenchymal stem cells. Eur J Immunol. 2006; 36(10):2566-73. DOI: 10.1002/eji.200636416. View

19.

Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D . Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4):315-7. DOI: 10.1080/14653240600855905. View

20.

Najar M, Raicevic G, Boufker H, Kazan H, De Bruyn C, Meuleman N . Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Cell Immunol. 2010; 264(2):171-9. DOI: 10.1016/j.cellimm.2010.06.006. View